These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 18804888)

  • 1. Treatment of the hepatitis B virus and hepatitis C virus co-infection: still a challenge for the hepatologist.
    Raimondo G; Saitta C
    J Hepatol; 2008 Nov; 49(5):677-9. PubMed ID: 18804888
    [No Abstract]   [Full Text] [Related]  

  • 2. The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated interferon-alpha2b and ribavirin in patients with HBV/HCV co-infection.
    Potthoff A; Wedemeyer H; Boecher WO; Berg T; Zeuzem S; Arnold J; Spengler U; Gruengreiff K; Kaeser T; Schuchmann M; Bergk A; Forestier N; Deterding K; Manns MP; Trautwein C;
    J Hepatol; 2008 Nov; 49(5):688-94. PubMed ID: 18490077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of occult hepatitis B virus infection or hepatitis B virus DNA integration on efficacy of chronic hepatitis C treatment with peginterferon and ribavirin: where are we?
    Hu KQ; Zhang YY
    J Clin Gastroenterol; 2014 Jan; 48(1):3-5. PubMed ID: 24045272
    [No Abstract]   [Full Text] [Related]  

  • 4. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Hamzaoui L; El Bouchtili S; Siai K; Mahmoudi M; Azzouz MM
    Clin Res Hepatol Gastroenterol; 2013 Feb; 37(1):e16-20. PubMed ID: 22959099
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virological profiles in hepatitis B virus/hepatitis C virus coinfected patients under interferon plus ribavirin therapy.
    Saitta C; Pontisso P; Brunetto MR; Fargion S; Gaeta GB; Niro GA; Picciotto A; Smedile A; Squadrito G; Raimondo G
    Antivir Ther; 2006; 11(7):931-4. PubMed ID: 17302256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.
    Senturk H; Tahan V; Canbakan B; Uraz S; Ulger Y; Ozaras R; Tabak F; Mert A; Ozbay G
    Neth J Med; 2008 May; 66(5):191-5. PubMed ID: 18490796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Treatment of cirrhotics].
    Galdame O; Jorge A; Sordá J
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S42-5. PubMed ID: 20214300
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained HCV-RNA response and hepatitis Bs seroconversion after individualized antiviral therapy with pegylated interferon alpha plus ribavirin and active vaccination in a hepatitis C virus/hepatitis B virus-coinfected patient.
    Potthoff A; Deterding K; Trautwein C; Rifai K; Manns MP; Wedemeyer H
    Eur J Gastroenterol Hepatol; 2007 Oct; 19(10):906-9. PubMed ID: 17873617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Combination therapy of interferon plus ribavirin for chronic hepatitis C].
    Asahina Y; Izumi N
    Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):467-73. PubMed ID: 15359843
    [No Abstract]   [Full Text] [Related]  

  • 10. Analysis of HCV co-infection with occult hepatitis B virus in patients undergoing IFN therapy.
    Khattab E; Chemin I; Vuillermoz I; Vieux C; Mrani S; Guillaud O; Trepo C; Zoulim F
    J Clin Virol; 2005 Jun; 33(2):150-7. PubMed ID: 15911431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment for chronic hepatitis C, more opportunity, more challenge].
    Wei L
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):481-3. PubMed ID: 19912676
    [No Abstract]   [Full Text] [Related]  

  • 12. [HCV-HBV infection].
    Imamura M; Chayama K
    Nihon Rinsho; 2006 Jul; 64(7):1310-3. PubMed ID: 16838649
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000 IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection.
    Lagging M; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Dhillon AP; Alsiö A; Hellstrand K; Westin J; Christensen P; Leutscher P; Norkrans G;
    Hepatology; 2008 Aug; 48(2):695. PubMed ID: 18666232
    [No Abstract]   [Full Text] [Related]  

  • 14. [Antiviral therapy for chronic viral hepatitis B and C].
    Iino S
    Nihon Rinsho; 2003 Feb; 61 Suppl 2():787-91. PubMed ID: 12722317
    [No Abstract]   [Full Text] [Related]  

  • 15. [Response criteria].
    Berbara D; Isla R; Manero E
    Acta Gastroenterol Latinoam; 2005 Jun; 35 Suppl 1():S36-7. PubMed ID: 20214296
    [No Abstract]   [Full Text] [Related]  

  • 16. Successful treatment of activated occult hepatitis B in a non-responder chronic hepatitis C patient.
    Emara MH; Radwan MI
    Virol J; 2011 Nov; 8():518. PubMed ID: 22078891
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peginterferon Alfa-2b and ribavirin for 12 versus 24 weeks in HCV infection.
    Henry MJ
    N Engl J Med; 2005 Sep; 353(11):1182-3; author reply 1182-3. PubMed ID: 16167381
    [No Abstract]   [Full Text] [Related]  

  • 18. [Spontaneous and treatment-induced virological dynamic in the plasma, PBMC and liver tissue in a patient with chronic HBV and HCV coinfection].
    Stanzione M; Tonsiello G; Iodice V; Macera M; Sagnelli E; Piccinino F; Coppola N
    Infez Med; 2009 Jun; 17(2):109-14. PubMed ID: 19602925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peginterferon alfa-2b plus ribavirin for chronic hepatitis.
    Picon PD; Costa AF; Kuchenbecker R; Beltrame A
    Lancet; 2002 Jan; 359(9302):263; author reply 264. PubMed ID: 11812597
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis B virus and hepatitis C virus co-infection: a therapeutic challenge.
    Coton T; Diallo I
    Clin Res Hepatol Gastroenterol; 2013 Jun; 37(3):e95. PubMed ID: 23663919
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.